Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
On June 17, 2026, Silo Pharma, Inc. received a formal notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the company has regained compliance with the minimum bid price requirement. Previously, on June 27, 2025, the company had been notified of non-compliance because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of Silo Pharmaβs common stock remained at or above $1.00 per share for at least ten consecutive business days, specifically from June 3, 2026, to June 16, 2026. Nasdaq now considers the matter closed, and the company's common stock will continue to be listed on the Nasdaq Capital Market. In the announcement, CEO Eric Weisblum also noted the company's continued progress toward a first-in-human clinical trial for its lead drug candidate, SPC-15, which targets PTSD.